Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the leading international forums in hematology, the meeting brings together experts worldwide to present advances in transplantation, cellular immunotherapy, and complication management, and remains an important platform shaping the future of hematologic treatment.
EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC

EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC

The 2026 European Association of Urology Annual Congress (EAU26), held in London, brought together leading experts from across the globe to discuss the latest advances in urology. Among the highlights, the final results of the HOPE-03 study, led by Prof. Peng Zhang and his team from West China Hospital, Sichuan University, were presented as an oral session, drawing significant international attention.
EAU26 Afternoon Dialogue | From Clinical Pain Points to Precision Diagnosis in Prostate Cancer — Insights from Prof. Kan Gong and Prof. Yi Liu’s Team

EAU26 Afternoon Dialogue | From Clinical Pain Points to Precision Diagnosis in Prostate Cancer — Insights from Prof. Kan Gong and Prof. Yi Liu’s Team

The 2026 European Association of Urology Annual Congress (EAU26), one of the most prestigious global meetings in urology, brought together leading advances in urologic oncology. Multiple studies on precision diagnosis of prostate cancer from the team led by Prof. Kan Gong and Prof. Yi Liu at Peking University First Hospital were selected for presentation, showcasing contributions from Chinese researchers on the international stage. Oncology Frontier invited Prof. Gong to share detailed insights into these findings.
ASCO GU On-site Report | Prof. Anna Wilkins: AI Pathology Model MMAI Breaks the Bottleneck in Prostate Cancer Risk Stratification, Unlocking a New Era of Personalized Genitourinary Oncology

ASCO GU On-site Report | Prof. Anna Wilkins: AI Pathology Model MMAI Breaks the Bottleneck in Prostate Cancer Risk Stratification, Unlocking a New Era of Personalized Genitourinary Oncology

During the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), a major breakthrough drew global attention: the first international external validation of the digital pathology–based AI predictive model MMAI in localized prostate cancer. Oncology Frontier – UroStream conducted an on-site interview with Prof. Anna Wilkins, Honorary Consultant in Clinical Oncology at The Institute of Cancer Research and The Royal Marsden Hospital (UK), who provided an in-depth interpretation of the study’s clinical value, real-world implementation prospects, and the broader advances highlighted at this year’s congress.
EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

The 2026 European Association of Urology Annual Congress (EAU26), held in London, once again served as a premier platform showcasing cutting-edge advances in urologic oncology. At this year’s meeting, Prof. Kan Gong and his team from Peking University First Hospital presented a series of impactful studies focusing on von Hippel–Lindau (VHL) syndrome–associated renal cell carcinoma in the Chinese population.
Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Blinatumomab, a CD19/CD3 bispecific antibody, has demonstrated clear efficacy in relapsed/refractory and MRD-positive B-cell acute lymphoblastic leukemia (B-ALL). Its integration into frontline therapy for newly diagnosed patients is now being actively explored and may reshape treatment paradigms.
Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential global conferences in hematopoietic stem cell transplantation, the meeting showcased cutting-edge research and the latest clinical advances in the field.
Voices from China at the EBMT Annual Meeting丨Prof. Hui Wang: An Early Myeloid Stem/Progenitor Cell–Based Immunophenotypic Panel Enables Rapid and Efficient Differentiation of APL from APL-Like AML

Voices from China at the EBMT Annual Meeting丨Prof. Hui Wang: An Early Myeloid Stem/Progenitor Cell–Based Immunophenotypic Panel Enables Rapid and Efficient Differentiation of APL from APL-Like AML

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. The conference focused on the latest advances in clinical hematology and hematopoietic stem cell transplantation, promoting continued progress in both clinical practice and translational research.
Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) carries an extremely poor prognosis, particularly in patients with high CD33 expression who are refractory to conventional salvage therapies, where treatment options remain very limited.